Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778405 | 0.85 | OPRM1 (0.34) | OPRM1MPOSMN1; SMN2 | |
| SCHEMBL1962737 | 0.85 | SMN1; SMN2 (0.41) | OPRM1MPOSMN1; SMN2CASP6 | |
| SCHEMBL562680 | 0.74 | MAPK10 (0.47) | CASP6 | |
| SCHEMBL1959860 | 0.74 | ALDH1A1 (0.41) | OPRM1MPOSMN1; SMN2CASP6 | |
| SCHEMBL1774871 | 0.73 | MTNR1A (0.46) | MPOSMN1; SMN2 | |
| SCHEMBL1958334 | 0.72 | L3MBTL1 (0.50) | CASP6 | |
| SCHEMBL1774519 | 0.71 | MPO (0.53) | OPRM1MPO | |
| SCHEMBL1775931 | 0.71 | MPO (0.53) | OPRM1MPO | |
| SCHEMBL1776729 | 0.71 | MPO (0.53) | OPRM1MPO | |
| SCHEMBL1946869 | 0.70 | KDM4E (0.56) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943625-B2 | Myeloperoxidase inhibitors; neuroinflammatory disorders; COPD; 3-(2-Ethoxy-2-methylpropyl)-2-thioxanthine | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20080221133-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | MPO, SERPINB1, XDH | OPRM1 587/4885MPO 1/4885SMN1; SMN2 3050/4885 |
| US-20080221133-A1 | Compounds | C1R, C1S, AKR1C3 | OPRM1 1235/4885MPO 1502/4885SMN1; SMN2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.